|
Canada-0-EXPLOSIVES Azienda Directories
|
Azienda News:
- Artificial Intelligence-Enabled Medical Devices | FDA
The AI-Enabled Medical Device List is a resource intended to identify AI-enabled medical devices that are authorized for marketing in the United States
- Roche granted FDA Breakthrough Device Designation for first AI-driven . . .
This is the first Breakthrough Device Designation to be granted for a computational pathology companion diagnostic (CDx) device “This FDA Breakthrough Device Designation is another example of our commitment to deliver innovation that enables more precise diagnosis in oncology,” said Matt Sause, CEO of Roche Diagnostics
- FDA Approval Process for Companion Diagnostics
This tutorial article explains the step-by-step FDA approval pathway for companion diagnostics, from pre-submission meetings to post-market responsibilities, with regulatory citations, examples, and real-world applications Step 1: Understanding Device Classification and Regulatory Pathways
- Beyond the Algorithm: How Real-World Data Is Transforming FDA Oversight . . .
Beyond the Algorithm: How Real-World Data Is Transforming FDA Oversight of AI-Enabled Medical Devices By hakamie November 3, 2025 Artificial intelligence (AI) is reshaping nearly every corner of healthcare — from diagnostic imaging and robotic surgery to remote patient monitoring and predictive analytics
- CAP25: FDA Approvals That Are Reshaping Pathology
This is the first FDA-approved IHC companion diagnostic to detect c-MET protein overexpression in non-squamous NSCLC It’s paired with AbbVie’s newly approved targeted therapy, Emrelis™ (telisotuzumab vedotin-tllv) Why does this matter? Because IHC is one of the most universal, established tools in pathology
- Augmented reality microscopy to bridge trust between AI and . . .
AI-based diagnostic pathology platforms are delivering unparalleled accuracy in cancer detection and, when fully integrated into real world practice, promise to shorten time to diagnosis and
- An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC - CURE
The Ventana TROP2 (EPR20043) RxDx Device, a computational pathology companion diagnostic (CDx), was granted breakthrough device designation by the U S Food and Drug Administration (FDA) for patients with non–small cell lung cancer, making it the first computational pathology CDx device to receive this designation
- The Current State Of FDA-Approved AI-Enabled Medical Devices
The FDA, a global leader in healthcare regulation, is adapting its framework to include AI-based medical devices, with 1400 approvals and clearances to date, indicating an acknowledgment of AI’s expanding role in healthcare
- FDA Has Now Cleared More Than 500 Healthcare AI . . . - Pathology News
There are now more than 520 marker-cleared artificial intelligence (AI) medical algorithms available in the United States, according to the U S Food and Drug Administration (FDA) as of January 2023 The vast majority of these are related to medical imaging
- US FDA Grants Breakthrough Device Designation for first AI-driven . . .
US FDA Grants Breakthrough Device Designation for first AI-driven Companion Diagnostic for Non-small Cell Lung Cancer » ADC Review The U S Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) RxDx Device This is the first Breakthrough Device Designation to be granted for a computational pathology companion diagnostic (CDx) device
|
|